--- title: "Amycretin: What the Trials Actually Show So Far" url: https://www.bodyhackguide.co/blog/amycretin-trial-evidence description: "Amycretin combines GLP-1 and amylin in one molecule. Read the published Lancet data, the 448-person type 2 diabetes trial and what the 22% headline leaves out." lang: en --- Skip to content Compare notes on r/BodyHackGuide (https://reddit.com/r/bodyhackguide) Compare notes with other researchers. Join r/BodyHackGuide (https://reddit.com/r/bodyhackguide) Research 5 min read Oct 22, 2026 Fact-checked (https://www.bodyhackguide.co/editorial-standards) # Amycretin: What the Trials Actually Show So Far Amycretin combines GLP-1 and amylin in one molecule. Read the published Lancet data, the 448-person type 2 diabetes trial and what the 22% headline leaves out. B BodyHackGuide Evidence notes from published research and trial registries. Educational information, not medical advice. Key Takeaway **Amycretin is an investigational unimolecular agonist of the GLP-1 and amylin receptors, developed by Novo Nordisk in once-weekly subcutaneous and once-daily oral forms.** Published phase 1b/2a data show mean weight loss of up to roughly 22% at 36 weeks on the highest subcutaneous dose, and a separate 448-person phase 2 trial in type 2 diabetes reported up to 14.5% weight loss at 36 weeks. Neither result is a prediction for an individual, and amycretin is not an approved medicine. Evidence checked October 22, 2026. This page explains human research, not purchasing, dosing or self-administration. ## What is amycretin? Most obesity medicines in development pick one lane: GLP-1 alone, GLP-1 plus GIP, or GLP-1 plus GIP plus glucagon. Amycretin pairs GLP-1 with amylin instead. Amylin is a hormone co-secreted with insulin that acts on satiety and gastric emptying, and it is the same target family as eloralintide and petrelintide. That makes amycretin a useful case study in mechanism language. "Dual agonist" describes what the molecule binds. It does not tell you how much weight any person will lose, and it does not make amycretin interchangeable with CagriSema, which combines two separate molecules (cagrilintide plus semaglutide) rather than one. ## What has actually been published? Two peer-reviewed papers exist, both in _The Lancet_, published June 20, 2025 and presented at the American Diabetes Association meeting: | Study | Design | What it found | What limits it | | --- | --- | --- | --- | | Subcutaneous amycretin phase 1b/2a | People with overweight or obesity; dose escalation and maintenance arms up to 36 weeks | Significantly greater weight loss than placebo across all tested doses; no weight-loss plateau observed by end of treatment | Small early-phase groups; short follow-up; not a phase 3 population | | Oral amycretin phase 1 | People with overweight or obesity | Significant weight reduction versus placebo; tolerability consistent with GLP-1 and amylin agonists | Phase 1 size and duration; oral peptides have large dose-to-effect variability | Source: Novo Nordisk's announcement of the Lancet publications and ADA 2025 presentation (https://www.globenewswire.com/news-release/2025/06/20/3102977/0/en/novo-nordisk-s-subcutaneous-and-oral-amycretin-data-published-in-the-lancet-and-presented-at-ada-2025.html). The widely quoted "up to 22%" figure comes from the highest-dose subcutaneous arm of the early trial. It is the best-performing group's mean, not the average across all arms, and not a maximum individual result. ## The 448-person diabetes trial On November 25, 2025, Novo Nordisk reported headline results from the first amycretin trial in people with type 2 diabetes: 448 participants inadequately controlled on metformin (about 40% also on an SGLT2 inhibitor), randomized to six once-weekly subcutaneous doses (0.4 mg to 40 mg), three once-daily oral doses (6 mg, 25 mg, 50 mg) or placebo, for up to 36 weeks. | Measure | Reported result | How to read it | | --- | --- | --- | | Weight loss, subcutaneous | Up to 14.5% at 36 weeks | Best arm, assuming full adherence; people with type 2 diabetes typically lose less than obesity-only populations | | HbA1c reduction, subcutaneous | Up to 1.8 percentage points from a 7.8% baseline | Dose-dependent | | HbA1c below 7%, subcutaneous | Up to 89.1% of participants | A threshold outcome, not a mean | | HbA1c reduction, oral | Up to 1.5 percentage points from an 8.0% baseline | Oral arm ran at lower effective exposure | | Safety | Mild to moderate gastrointestinal events, consistent with incretin and amylin drugs | Topline description; full paper not yet published | Sources: Novo Nordisk's November 25, 2025 announcement (https://www.nasdaq.com/press-release/novo-nordisk-phase-2-trial-amycretin-reports-significant-weight-loss-and-hba1c) and Reuters coverage (https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisks-obesity-drug-shows-weight-loss-up-145-mid-stage-study-2025-11-25/). The trial registration is NCT06542874 (https://clinicaltrials.gov/study/NCT06542874). These are company-reported topline results. The peer-reviewed paper had not been published at the time of writing, so arm-level discontinuation counts and full adverse-event tables are not yet checkable. ## Why the diabetes number is lower than the obesity number 14.5% in the diabetes trial versus roughly 22% in the obesity trial is not a contradiction. People with type 2 diabetes consistently lose less weight on incretin-class drugs than people without diabetes, the trials used different dose ranges, and the diabetes population was on background metformin with or without an SGLT2 inhibitor. Comparing the two headlines without that context manufactures a story that isn't there. ## What remains unknown Phase 3 trials are planned but their results do not exist yet. Open questions include long-term durability after stopping, rare adverse events that a few hundred participants cannot detect, cardiovascular outcomes, and how amycretin performs against tirzepatide or retatrutide in a head-to-head design. No such comparison trial exists. For a compound in the same amylin lane with published phase 2 data, see our eloralintide evidence review (https://www.bodyhackguide.co/blog/eloralintide-phase-2-results). For the triple-agonist comparison, see UBT251's phase 2 results (https://www.bodyhackguide.co/blog/ubt251-phase-2-results). ## Sources and related research - Lancet publications and ADA 2025 presentation announcement: https://www.globenewswire.com/news-release/2025/06/20/3102977/0/en/novo-nordisk-s-subcutaneous-and-oral-amycretin-data-published-in-the-lancet-and-presented-at-ada-2025.html - Phase 2 type 2 diabetes topline announcement, November 25, 2025: https://www.nasdaq.com/press-release/novo-nordisk-phase-2-trial-amycretin-reports-significant-weight-loss-and-hba1c - Reuters coverage of the phase 2 results: https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisks-obesity-drug-shows-weight-loss-up-145-mid-stage-study-2025-11-25/ - Trial registration NCT06542874: https://clinicaltrials.gov/study/NCT06542874 - Eloralintide: the other amylin-mechanism evidence story: https://www.bodyhackguide.co/blog/eloralintide-phase-2-results - Petrelintide: ZUPREME-1 phase 2 results: https://www.bodyhackguide.co/blog/petrelintide-zupreme-1-results ## Frequently asked No. Amycretin is a single molecule that activates GLP-1 and amylin receptors. CagriSema is a combination of two separate molecules, cagrilintide (an amylin analogue) and semaglutide (a GLP-1 agonist). Same target family, different chemistry. ## Related Articles Research ### UBT251: Phase 2 Results and the 19.7% Weight-Loss Claim Read https://www.bodyhackguide.co/blog/ubt251-phase-2-results Research ### Eloralintide: Amylin and the Phase 2 Weight-Loss Results Read https://www.bodyhackguide.co/blog/eloralintide-phase-2-results Research ### P11-4 and Curodont: What Enamel-Repair Trials Show Read https://www.bodyhackguide.co/blog/p11-4-enamel-repair-evidence Research ### Petrelintide: ZUPREME-1 Results and the Tolerability Claim Read https://www.bodyhackguide.co/blog/petrelintide-zupreme-1-results ## New guides, by email New compound guides and research notes when we publish them. No set schedule. Unsubscribe anytime. No spam. Unsubscribe anytime. Share this article: 𝕏 / Twitter (https://twitter.com/intent/tweet?text=Amycretin%3A%20What%20the%20Trials%20Actually%20Show%20So%20Far&url=https%3A%2F%2Fwww.bodyhackguide.co%2Fblog%2Famycretin-trial-evidence) B BodyHackGuide (https://www.bodyhackguide.co/about)Research editorial Join r/BodyHackGuide on Reddit: https://reddit.com/r/bodyhackguide Join Discord: https://discord.gg/Mhq5UdRYBA | About the author: https://www.bodyhackguide.co/about Back to all articles: https://www.bodyhackguide.co/blog Image: BodyHackGuide (https://www.bodyhackguide.co/assets/bodyhackguide-logo-DOzZNUyh.webp) ### BodyHackGuide Your biohacking research hub: compound pricing, brain health protocols, dosing tools, and vendor reviews. support@bodyhackguide.co Join our Discord: https://discord.gg/Mhq5UdRYBA r/BodyHackGuide on Reddit: https://reddit.com/r/BodyHackGuide #### Explore - Compare prices: https://www.bodyhackguide.co/compare - Vendors: https://www.bodyhackguide.co/vendors - Deals: https://www.bodyhackguide.co/deals - Coupons: https://www.bodyhackguide.co/coupons - Nootropics: https://www.bodyhackguide.co/nootropics - Brain health: https://www.bodyhackguide.co/brain-health - Blog: https://www.bodyhackguide.co/blog - Guides: https://www.bodyhackguide.co/guides #### Tools - Reconstitution: https://www.bodyhackguide.co/tools/reconstitution - Half-life visualizer: https://www.bodyhackguide.co/tools/halflife - COA reader: https://www.bodyhackguide.co/tools/coa - Cost calculator: https://www.bodyhackguide.co/tools/cost-calculator - Stack builder: https://www.bodyhackguide.co/stack-builder - All tools: https://www.bodyhackguide.co/tools #### Trust & vendors - Vendor directory: https://www.bodyhackguide.co/vendors - Trust scorecard: https://www.bodyhackguide.co/vendors/scorecard - Vendor trust badge: https://www.bodyhackguide.co/vendors/get-vetted - Scoring methodology: https://www.bodyhackguide.co/vendors/methodology - Peptide cheat sheet: https://www.bodyhackguide.co/guides/peptide-cheat-sheet-download #### Company - About: https://www.bodyhackguide.co/about - Affiliate disclosure: https://www.bodyhackguide.co/affiliate-disclosure - Editorial standards: https://www.bodyhackguide.co/editorial-standards - Creators: https://www.bodyhackguide.co/creators - Coaches: https://www.bodyhackguide.co/coaches - 1-on-1 coaching: https://www.bodyhackguide.co/coaching - Privacy: https://www.bodyhackguide.co/privacy - Terms: https://www.bodyhackguide.co/terms - Full site directory: https://www.bodyhackguide.co/site-directory **Affiliate Disclosure:** We rank every vendor on the same public, reproducible methodology (https://www.bodyhackguide.co/vendors/methodology), and we earn a commission from purchases made through some of our links at no extra cost to you. Full details in our affiliate disclosure (https://www.bodyhackguide.co/affiliate-disclosure). **Research Disclaimer:** All compounds listed are for laboratory and research purposes only. Not for human consumption. This site does not sell or ship any products. Always consult a qualified healthcare professional and comply with local regulations. © 2026 BodyHackGuide. All rights reserved. · Terms (https://www.bodyhackguide.co/terms) · Privacy (https://www.bodyhackguide.co/privacy) ## Structured data ```json [ { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://www.bodyhackguide.co/" }, { "@type": "ListItem", "position": 2, "name": "Blog", "item": "https://www.bodyhackguide.co/blog" }, { "@type": "ListItem", "position": 3, "name": "Amycretin: What the Trials Actually Show So Far" } ] }, { "@context": "https://schema.org", "@type": "BlogPosting", "headline": "Amycretin: What the Trials Actually Show So Far", "description": "Amycretin combines GLP-1 and amylin in one molecule. Read the published Lancet data, the 448-person type 2 diabetes trial and what the 22% headline leaves out.", "datePublished": "2026-10-22T00:30:00Z", "dateModified": "2026-10-22T00:30:00Z", "author": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co/about" }, "publisher": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co", "logo": { "@type": "ImageObject", "url": "https://www.bodyhackguide.co/bhglogo.png" } }, "mainEntityOfPage": "https://www.bodyhackguide.co/blog/amycretin-trial-evidence", "wordCount": 975, "timeRequired": "PT5M", "articleSection": "Research", "inLanguage": "en-US", "isAccessibleForFree": true, "speakable": { "@type": "SpeakableSpecification", "cssSelector": [ "h1", ".blog-tldr", "article p:first-of-type" ] } }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Is amycretin the same as CagriSema?", "acceptedAnswer": { "@type": "Answer", "text": "No. Amycretin is a single molecule that activates GLP-1 and amylin receptors. CagriSema is a combination of two separate molecules, cagrilintide (an amylin analogue) and semaglutide (a GLP-1 agonist). Same target family, different chemistry." } }, { "@type": "Question", "name": "Is amycretin approved?", "acceptedAnswer": { "@type": "Answer", "text": "No. It is investigational. Phase 3 programs have been announced but no regulatory approval exists anywhere." } }, { "@type": "Question", "name": "Why do some sources say 22% and others 14.5%?", "acceptedAnswer": { "@type": "Answer", "text": "They come from different trials. The roughly 22% figure is the highest-dose arm of the early obesity trial. The 14.5% figure is the best arm of the 448-person trial in people with type 2 diabetes, a population that typically loses less weight on this drug class." } }, { "@type": "Question", "name": "Is oral amycretin as strong as the injection?", "acceptedAnswer": { "@type": "Answer", "text": "The published data show the oral form produces meaningful weight loss and HbA1c reductions, but at lower magnitude than the subcutaneous form in the studies so far. Oral peptides generally require much larger doses to reach similar exposure." } } ] }, { "@context": "https://schema.org", "@type": "Organization", "@id": "https://www.bodyhackguide.co#organization", "name": "BodyHackGuide", "alternateName": "BHG", "url": "https://www.bodyhackguide.co", "logo": { "@type": "ImageObject", "url": "https://www.bodyhackguide.co/logo.png", "width": 512, "height": 512 }, "description": "Evidence-based research reference for peptides and nootropics. 273 compound profiles, interactive dosing calculators, vendor price comparisons, and trust-scored vendor reviews scored on a public, reproducible methodology applied to every vendor. We earn a commission on purchases through some of our links.", "foundingDate": "2024", "founder": { "@id": "https://www.bodyhackguide.co/about#person" }, "sameAs": [ "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher", "https://discord.gg/Mhq5UdRYBA" ], "knowsAbout": [ "Peptide research", "Nootropic research", "Biohacking", "Compound dosing", "Vendor transparency" ], "publishingPrinciples": "https://www.bodyhackguide.co/editorial-standards", "ethicsPolicy": "https://www.bodyhackguide.co/editorial-standards", "diversityPolicy": "https://www.bodyhackguide.co/editorial-standards" } ] ```